VA launches study to unlock kidney protection secrets in High-Risk veterans
NCT ID NCT07155694
Summary
This study aims to understand how two kidney-protective medications, finerenone and empagliflozin, work in African American veterans with diabetes-related kidney disease. Researchers will measure specific markers of kidney injury in urine and blood to see how these drugs affect kidney cell health and inflammation. The goal is to learn more about why these medications help and if using them together provides extra benefit for this high-risk group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington DC Veterans Affairs Medical Center (688)
Washington D.C., District of Columbia, 20422, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.